The kidney disease market size has grown strongly in recent years. It will grow from $114.39 billion in 2025 to $121.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, increasing incidence of diabetes and hypertension, established use of dialysis and medication therapies, growth in hospital-based renal care, expanding availability of diagnostic testing.
The kidney disease market size is expected to see strong growth in the next few years. It will grow to $159.58 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to aging global population with higher renal risk, increasing adoption of home-based dialysis, rising investment in kidney disease research, growing focus on early screening programs, expanding access to renal care in emerging markets. Major trends in the forecast period include rising focus on early detection and disease management, growing adoption of dialysis and renal replacement therapies, increasing demand for personalized kidney disease treatment, expansion of multidisciplinary care models for renal patients, improved patient awareness and preventive care initiatives.
The rising prevalence of kidney diseases is anticipated to drive the growth of the kidney disease market in the coming years. Kidney diseases encompass a range of conditions that impact the structure and function of the kidneys. Medications for kidney disorders help lower blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. For example, in June 2023, Kidney Research UK, a UK-based charitable organization focused on research and advocacy to improve understanding, prevention, and treatment of kidney diseases, reported that approximately 7.19 million people in the UK were living with chronic kidney disease, accounting for over 10% of the population, with this number projected to rise to 7.61 million by 2033. Consequently, the growing prevalence of kidney diseases is fueling the expansion of the kidney disease market.
Major companies in the kidney disease market are emphasizing technology-driven innovations, such as compact, cartridge-based hemodialysis systems, to improve treatment flexibility, patient usability, and workflow efficiency. These systems are portable dialysis devices that utilize disposable dialysate cartridges instead of traditional bagged fluids, offering features like automated dialysate preparation, simplified setup, and enhanced suitability for home-based therapy. For example, in November 2024, Quanta Dialysis Technologies, a UK-based dialysis technology company, received FDA clearance for the Quanta Dialysis System, a cartridge-based hemodialysis device designed for home hemodialysis and flexible care-setting deployment. The system features a compact footprint, on-demand dialysate generation, and an intuitive touchscreen interface, improving patient autonomy, ease of treatment delivery, and operational efficiency across dialysis settings.
In January 2023, AstraZeneca Pharmaceuticals LP, a U.S.-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. With this acquisition, AstraZeneca aims to strengthen its cardiorenal portfolio by integrating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) developed to reduce blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for kidney diseases.
Major companies operating in the kidney disease market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Vertex Pharmaceuticals Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Aurobindo Pharma Limited.
North America was the largest region in the kidney disease market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the kidney disease market by increasing the cost of imported dialysis equipment, diagnostic devices, and pharmaceutical raw materials used in renal treatments. Treatment segments such as dialysis and surgical interventions are most affected, particularly in North America and Europe due to reliance on global medical supply chains. Hospitals and diagnostic laboratories face higher procurement and operational costs, which may influence overall treatment affordability. However, tariffs have also encouraged local manufacturing of renal care equipment, strengthened regional sourcing, and supported long-term supply chain resilience in kidney disease management.
The kidney disease market research report is one of a series of new reports that provides kidney disease market statistics, including kidney disease industry global market size, regional shares, competitors with a kidney disease market share, detailed kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the kidney disease industry. This kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kidney diseases encompass a range of conditions that impair the structure and function of the kidneys. The kidneys are essential organs that filter waste products and excess fluids from the blood, maintain electrolyte balance, and produce hormones involved in regulating blood pressure and the production of red blood cells.
The primary treatment options for kidney disease include medication, dialysis, surgery, and others. Medication involves the use of drugs or pharmaceutical agents to treat, manage, or prevent medical conditions associated with kidney disorders. These treatments are prescribed for acute kidney injury, chronic kidney disease, end-stage renal disease, and other related conditions, and are administered through oral and parenteral routes. They are utilized by various end users, including hospitals, diagnostic laboratories, and others.
The kidney disease market consists of revenues earned by providing services such as hemodialysis, peritoneal dialysis, and kidney transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney disease also includes sales of drugs like galafold, sibnayal, tarpeyo, and cystadrops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The kidney disease market size is expected to see strong growth in the next few years. It will grow to $159.58 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to aging global population with higher renal risk, increasing adoption of home-based dialysis, rising investment in kidney disease research, growing focus on early screening programs, expanding access to renal care in emerging markets. Major trends in the forecast period include rising focus on early detection and disease management, growing adoption of dialysis and renal replacement therapies, increasing demand for personalized kidney disease treatment, expansion of multidisciplinary care models for renal patients, improved patient awareness and preventive care initiatives.
The rising prevalence of kidney diseases is anticipated to drive the growth of the kidney disease market in the coming years. Kidney diseases encompass a range of conditions that impact the structure and function of the kidneys. Medications for kidney disorders help lower blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. For example, in June 2023, Kidney Research UK, a UK-based charitable organization focused on research and advocacy to improve understanding, prevention, and treatment of kidney diseases, reported that approximately 7.19 million people in the UK were living with chronic kidney disease, accounting for over 10% of the population, with this number projected to rise to 7.61 million by 2033. Consequently, the growing prevalence of kidney diseases is fueling the expansion of the kidney disease market.
Major companies in the kidney disease market are emphasizing technology-driven innovations, such as compact, cartridge-based hemodialysis systems, to improve treatment flexibility, patient usability, and workflow efficiency. These systems are portable dialysis devices that utilize disposable dialysate cartridges instead of traditional bagged fluids, offering features like automated dialysate preparation, simplified setup, and enhanced suitability for home-based therapy. For example, in November 2024, Quanta Dialysis Technologies, a UK-based dialysis technology company, received FDA clearance for the Quanta Dialysis System, a cartridge-based hemodialysis device designed for home hemodialysis and flexible care-setting deployment. The system features a compact footprint, on-demand dialysate generation, and an intuitive touchscreen interface, improving patient autonomy, ease of treatment delivery, and operational efficiency across dialysis settings.
In January 2023, AstraZeneca Pharmaceuticals LP, a U.S.-based biopharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. With this acquisition, AstraZeneca aims to strengthen its cardiorenal portfolio by integrating CinCor's promising compound, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) developed to reduce blood pressure in patients with treatment-resistant hypertension, including those with chronic kidney disease. CinCor Pharma Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for kidney diseases.
Major companies operating in the kidney disease market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Vertex Pharmaceuticals Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Aurobindo Pharma Limited.
North America was the largest region in the kidney disease market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the kidney disease market by increasing the cost of imported dialysis equipment, diagnostic devices, and pharmaceutical raw materials used in renal treatments. Treatment segments such as dialysis and surgical interventions are most affected, particularly in North America and Europe due to reliance on global medical supply chains. Hospitals and diagnostic laboratories face higher procurement and operational costs, which may influence overall treatment affordability. However, tariffs have also encouraged local manufacturing of renal care equipment, strengthened regional sourcing, and supported long-term supply chain resilience in kidney disease management.
The kidney disease market research report is one of a series of new reports that provides kidney disease market statistics, including kidney disease industry global market size, regional shares, competitors with a kidney disease market share, detailed kidney disease market segments, market trends and opportunities, and any further data you may need to thrive in the kidney disease industry. This kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Kidney diseases encompass a range of conditions that impair the structure and function of the kidneys. The kidneys are essential organs that filter waste products and excess fluids from the blood, maintain electrolyte balance, and produce hormones involved in regulating blood pressure and the production of red blood cells.
The primary treatment options for kidney disease include medication, dialysis, surgery, and others. Medication involves the use of drugs or pharmaceutical agents to treat, manage, or prevent medical conditions associated with kidney disorders. These treatments are prescribed for acute kidney injury, chronic kidney disease, end-stage renal disease, and other related conditions, and are administered through oral and parenteral routes. They are utilized by various end users, including hospitals, diagnostic laboratories, and others.
The kidney disease market consists of revenues earned by providing services such as hemodialysis, peritoneal dialysis, and kidney transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney disease also includes sales of drugs like galafold, sibnayal, tarpeyo, and cystadrops. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Kidney Disease Market Characteristics
3. Kidney Disease Market Supply Chain Analysis
4. Global Kidney Disease Market Trends and Strategies
5. Kidney Disease Market Analysis of End Use Industries
7. Global Kidney Disease Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Kidney Disease Total Addressable Market (TAM) Analysis for the Market
9. Kidney Disease Market Segmentation
10. Kidney Disease Market Regional and Country Analysis
11. Asia-Pacific Kidney Disease Market
12. China Kidney Disease Market
13. India Kidney Disease Market
14. Japan Kidney Disease Market
15. Australia Kidney Disease Market
16. Indonesia Kidney Disease Market
17. South Korea Kidney Disease Market
18. Taiwan Kidney Disease Market
19. South East Asia Kidney Disease Market
20. Western Europe Kidney Disease Market
21. UK Kidney Disease Market
22. Germany Kidney Disease Market
23. France Kidney Disease Market
24. Italy Kidney Disease Market
25. Spain Kidney Disease Market
26. Eastern Europe Kidney Disease Market
27. Russia Kidney Disease Market
28. North America Kidney Disease Market
29. USA Kidney Disease Market
30. Canada Kidney Disease Market
31. South America Kidney Disease Market
32. Brazil Kidney Disease Market
33. Middle East Kidney Disease Market
34. Africa Kidney Disease Market
36. Kidney Disease Market Competitive Landscape and Company Profiles
37. Kidney Disease Market Other Major and Innovative Companies
40. Kidney Disease Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Kidney Disease Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for kidney disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The kidney disease market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment: Medication; Dialysis; Surgery; Other Treatments2) By Indication: Acute Kidney Injury; Chronic Kidney Disease; End-Stage Renal Disease; Other Indications
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Medication: Antihypertensives; Erythropoiesis-Stimulating Agents (ESAs); Phosphate Binders; Vitamin D Analogs; Immunosuppressants2) By Dialysis: Hemodialysis; Peritoneal Dialysis
3) By Surgery: Kidney Transplant; Nephrectomy; Renal Artery Bypass; Ureteral Surgery
4) By Other Treatments: Lifestyle And Dietary Modifications; Renal Replacement Therapy; Palliative Care
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; AstraZeneca plc; Sanofi S.A.; Bristol-Myers Squibb Company; AbbVie Inc.; Bayer AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Boehringer Ingelheim International GmbH; Astellas Pharma Inc.; Otsuka Pharmaceutical Co. Ltd.; Mitsubishi Tanabe Pharma Corporation; Kyowa Kirin Co. Ltd.; Vertex Pharmaceuticals Inc.; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; Cipla Limited; Lupin Limited; Aurobindo Pharma Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Kidney Disease market report include:- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- AstraZeneca plc
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Bayer AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Astellas Pharma Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Kyowa Kirin Co. Ltd.
- Vertex Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Cipla Limited
- Lupin Limited
- Aurobindo Pharma Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 121.98 Billion |
| Forecasted Market Value ( USD | $ 159.58 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
